NVS
Novartis AG
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: NVS
- PEG Ratio
NVS's PE to growth ratio is not computable because the earnings growth data is negative or zero. Historical data from March 2026 shows Novartis AG with a PEG ratio of 2.37.
NVS PEG ratio history
Novartis AG's nine years historical PEG ratio has a mean of 0.47. NVS hit its maximum PEG ratio of 2.37 during the Mar 2026 quarter over the last nine years. The Dec 2021 quarter marked the lowest reading at 0.04, indicating the most favorable growth-adjusted valuation.
Novartis AG PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.88 | 19.12 | 21.8% |
| 2024 | N/A | 16.44 | -17.2% |
| 2023 | 0.11 | 14.12 | 124.1% |
| 2022 | N/A | 28.44 | -70.2% |
| 2021 | 0.04 | 8.17 | 201.7% |
| 2020 | N/A | 26.6 | -30.7% |
| 2019 | N/A | 18.49 | -5.9% |
| 2018 | 0.24 | 15.77 | 65.9% |
| 2017 | 1.57 | 25.6 | 16.3% |
| 2016 | N/A | 25.83 | -61.9% |
| 2015 | 0.15 | 11.63 | 75.8% |
| 2014 | 1.83 | 22.01 | 12% |
| 2013 | N/A | 21.38 | -1.8% |
| 2012 | 7.87 | 16.53 | 2.1% |
| 2011 | N/A | 15.25 | -12.4% |
Novartis AG PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | N/A | 23.53 | -3.5% |
| Mar 2026 | 2.37 | 21.76 | 9.2% |
| Dec 2025 | 0.88 | 19.12 | 21.8% |
| Sep 2025 | N/A | 17.42 | -14.3% |
| Jun 2025 | N/A | 17.54 | -12.2% |
| Mar 2025 | N/A | 17.34 | -12.8% |
| Dec 2024 | N/A | 16.44 | -17.2% |
| Sep 2024 | 0.1 | 13.39 | 129.7% |
| Jun 2024 | 0.12 | 13.54 | 117.1% |
| Mar 2024 | 0.11 | 13.12 | 124.7% |
| Dec 2023 | 0.11 | 14.12 | 124.1% |
| Sep 2023 | N/A | 27.24 | -61.8% |
| Jun 2023 | N/A | 27.88 | -64.8% |
| Mar 2023 | N/A | 28.05 | -69.6% |
| Dec 2022 | N/A | 28.44 | -70.2% |
NVS average PEG ratio chart
PEG comparison
NVS EPS growth
NVS Price vs fair value
NVS PEG vs peers
| Stock name | PEG ratio | Market cap |
|---|---|---|
| TEVA Teva- Pharmaceutical Industries Ltd | 0.1 | $39.65B |
| BMY Bristol-Myers Squibb Company | 0.17 | $131.84B |
| AZN Astrazeneca plc | 0.89 | $241.13B |
| PFE Pfizer Inc | N/A | $142.37B |
| MRK Merck & Co Inc | N/A | $316.38B |
| JNJ Johnson & Johnson | N/A | $607.73B |
| ABT Abbott Laboratories | N/A | $185.72B |
| NVS Novartis AG | N/A | $293.47B |
Frequently asked questions
What is Novartis AG's PEG ratio?
NVS's PEG ratio cannot be computed because EPS growth data is negative or not present.
What is the 3-year average PEG ratio for Novartis AG (NVS)?
NVS's 3-year PEG ratio average is 0.62.
What is the 5-year average PEG ratio for Novartis AG (NVS)?
NVS's 5-year PEG ratio average is 0.4.
What is the highest PEG ratio for NVS?
In the last nine years, NVS's peak PEG ratio of 2.37 occurred in the Mar 2026 quarter.
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.